| 摘要: |
| 目的 探究乳腺癌不同病理特征患者超声乳腺影像报告和数据系统(BI-RADS)分级、声触诊组织量化(VTIQ)技术参数和糖类抗原153(CA153)的差异。方法 回顾性分析我院106例经术后病理确诊的乳腺癌患者临床资料,术前均接受常规超声检查进行BI-RADS分级,接受VTIQ技术检查测量病灶剪切波速度(SWVmax),经酶联免疫吸附法检测CA153,分析上述检测结果与临床病理特征的关系。结果 乳腺癌各病理类型、组织学分级、肿瘤大小、病理分子分型间的超声BI-RADS分级分布、CA153水平比较差异均无统计学意义(P>0.05)；浸润性小叶癌者SWVmax高于导管内原位癌、浸润性导管癌、其他者,浸润性导管癌、其他者SWVmax高于导管内原位癌,差异有统计学意义(P<0.05)；组织学分级3级者SWVmax高于2级、1级者,2级者SWVmax高于1级者,差异有统计学意义(P<0.05)；病理分子分型中Luminal B(HER2+)者SWVmax最高,且高于Luminal A、Luminal B(HER2-)、Luminal B(HER2+)、三阴型者,Luminal A者SWVmax最低,且均低于其他分子分型者,差异有统计学意义(P<0.05)；乳腺癌淋巴结未转移者BI-RADS分级3~4a级分布多于转移者,SWVmax、CA153水平高于转移者,差异有统计学意义(P<0.05)。结论 超声BI-RADS分级、CA153水平与乳腺癌患者淋巴结转移状态有关,VTIQ技术参数SWVmax与病理类型、组织学分级、肿瘤大小、病理分子分型、淋巴结转移状态均有关,可为乳腺癌临床诊断和病情评估提供有效参考信息。 |
| 关键词: 超声BI-RADS分级 VTIQ技术参数 CA153 乳腺癌 临床病理特征 |
| DOI： |
| 投稿时间：2023-01-05修订日期：2023-03-22 |
| 基金项目:海南省卫生健康行业科研项目 项目编号: 20A200366 |
|
| Differences in ultrasound BI-RADS grading, VTIQ technical parameter and CA153 in patients with breast cancer of different pathological characteristics |
| liuxiaolan,zhangyaqin,maixiangxiang,sunzhangxiu |
| () |
| Abstract: |
| Objective To explore the differences in ultrasound breast imaging reporting and data system (BI-RADS) grading, virtual touch tissue imaging quantification (VTIQ) technical parameter and carbohydrate antigen 153 (CA153) in patients with breast cancer of different pathological characteristics. Methods The clinical data of 106 patients with breast cancer diagnosed by postoperative pathology in the hospital were retrospectively analyzed. Before surgery, all the patients received conventional ultrasonography for BI-RADS grading and underwent VTIQ technology to detect the maximum shear wave velocity (SWVmax) of lesions. CA153 was detected by immunosorbent assay, and the relationship between the above detection results and clinicopathological characteristics was analyzed. Results There were no statistical differences in the ultrasound BI-RADS grading distribution and CA153 level among different pathological types, histological grades, tumor sizes and pathological molecular types of breast cancer (P>0.05). The SWVmax of patients with invasive lobular carcinoma was higher than that of patients with ductal carcinoma in situ, invasive ductal carcinoma and other disease, and the SWVmax of patients with invasive ductal carcinoma and other disease was higher than that of patients with ductal carcinoma in situ (P<0.05). The SWVmax was higher in patients with histological grade 3 than grade 2 or 1, and was higher in patients with grade 2 than grade 1 (P<0.05). According to pathological molecular typing, Luminal B (HER2+) had the highest SWVmax, which was higher than that of Luminal A, Luminal B (HER2-), Luminal B (HER2+) and triple-negative type. The SWVmax wasthe lowest in Luminal A, which was lower than other molecular types (P<0.05). The distribution of BI-RADS grades 3-4a in breast cancer patients without lymph node metastasis was more than that in patients with metastasis, and the SWVmax and CA153 were higher than those in patients with metastasis (P<0.05). Conclusion Ultrasound BI-RADS grading and CA153 level are related to the status of lymph node metastasis in patients with breast cancer, and VTIQ technical parameter SWVmax is associated with pathological type, histological grade, tumor size, pathological molecular type and lymph node metastasis, which can provide effective reference information for the clinical diagnosis and disease evaluation of breast cancer. |
| Key words: Ultrasound BI-RADS grading VTIQ technical parameter CA153 Breast cancer Clinicopathological characteristics |
